MXPA05009526A - Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. - Google Patents

Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.

Info

Publication number
MXPA05009526A
MXPA05009526A MXPA05009526A MXPA05009526A MXPA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A
Authority
MX
Mexico
Prior art keywords
cancer
viral infection
therapeutic treatment
myxoma virus
chronic viral
Prior art date
Application number
MXPA05009526A
Other languages
English (en)
Inventor
John C Bell
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of MXPA05009526A publication Critical patent/MXPA05009526A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere al uso terapeutico de virus de Mixoma. El virus de Mixoma puede infectar selectivamente las celulas que tengan una respuesta anti-viral innata deficiente, incluyendo las celulas que no respondan al interferon, y se puede utilizar para tratar enfermedades caracterizadas por la presencia de estas celulas, incluyendo cancer.
MXPA05009526A 2003-03-07 2004-03-08 Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. MXPA05009526A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US45539303P 2003-03-18 2003-03-18
PCT/CA2004/000341 WO2004078206A1 (en) 2003-03-07 2004-03-08 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection

Publications (1)

Publication Number Publication Date
MXPA05009526A true MXPA05009526A (es) 2005-12-15

Family

ID=32965588

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009526A MXPA05009526A (es) 2003-03-07 2004-03-08 Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.

Country Status (12)

Country Link
US (2) US7582614B2 (es)
EP (1) EP1601376B1 (es)
JP (2) JP4800924B2 (es)
KR (1) KR101116858B1 (es)
AU (1) AU2004216928B2 (es)
CA (1) CA2517147C (es)
HK (1) HK1081099A1 (es)
IL (1) IL170601A (es)
MX (1) MXPA05009526A (es)
NZ (1) NZ541951A (es)
RU (1) RU2362584C2 (es)
WO (1) WO2004078206A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541951A (en) * 2003-03-07 2008-03-28 Robarts Res Inst Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
CN101137748B (zh) * 2005-03-07 2011-12-14 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
WO2007143538A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a enhances infection by myxoma virus
AU2007256754B2 (en) 2006-06-01 2012-11-29 Robarts Research Institute Myxoma virus mutants for cancer treatment
PT2717887T (pt) * 2011-06-09 2018-04-04 Univ Florida Métodos para tratamento ou prevenção da doença do enxerto contra hospedeiro
EP3512533B9 (en) * 2016-11-17 2021-05-19 VCN Biosciences SL Oncolytic viral vectors for use in the treatment of retinoblastoma
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh TUMOR ORGANOID MODEL
KR20190109379A (ko) * 2018-03-16 2019-09-25 바이로큐어 주식회사 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020036341A1 (ko) * 2018-08-17 2020-02-20 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
MX2021002668A (es) * 2018-09-05 2021-05-12 Univ Arizona State Plataforma de virus oncolitico para tratar el cancer hematologico.
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP1314430A1 (en) 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
AU8576298A (en) 1997-07-18 1999-02-10 Chiron Corporation Lentiviral vectors
CA2305269C (en) 1997-10-09 2012-07-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
EP1390046A4 (en) 1999-04-15 2005-04-20 Wellstat Biologics Corp TREATMENT OF NEOPLASMS WITH VIRUSES
EP1200595A2 (en) 1999-07-12 2002-05-02 Viron Therapeutics, Inc. Myxoma virus genes for immune modulation
NZ541951A (en) * 2003-03-07 2008-03-28 Robarts Res Inst Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments

Also Published As

Publication number Publication date
RU2362584C2 (ru) 2009-07-27
US20090317362A1 (en) 2009-12-24
CA2517147C (en) 2011-06-14
KR20050111349A (ko) 2005-11-24
HK1081099A1 (en) 2006-05-12
AU2004216928C1 (en) 2007-03-08
KR101116858B1 (ko) 2012-03-06
JP4800924B2 (ja) 2011-10-26
JP2006519789A (ja) 2006-08-31
JP2011157399A (ja) 2011-08-18
RU2005131020A (ru) 2006-03-10
AU2004216928A1 (en) 2004-09-16
AU2004216928B2 (en) 2007-03-08
IL170601A (en) 2010-11-30
CA2517147A1 (en) 2004-09-16
EP1601376B1 (en) 2012-05-30
NZ541951A (en) 2008-03-28
WO2004078206A1 (en) 2004-09-16
EP1601376A1 (en) 2005-12-07
US8227440B2 (en) 2012-07-24
US20060263333A1 (en) 2006-11-23
US7582614B2 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
MX2007010962A (es) Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico.
MXPA05009526A (es) Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
WO2010118367A3 (en) Antiviral pyrimidines
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
WO2006133099A3 (en) Sirna microbicides for preventing and treating viral diseases
WO2008096831A1 (ja) 癌の治療剤
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
TW200633995A (en) Andrographolide derivatives to treat viral infections
WO2009061395A3 (en) Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
LT2003009A (en) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
EA201101036A1 (ru) Применение хлорида аммония в терапии
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2002026249A3 (en) Methods for inhibition of viral infection
WO2019068905A3 (en) Feline vaccines conferring early protection
WO2004018002A3 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
WO2000069455A3 (de) Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus
WO2003015714A3 (en) Compositions and therapeutic methods for viral infection
UA87266C2 (ru) Применение вируса миксомы для лечения рака
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection

Legal Events

Date Code Title Description
FG Grant or registration